ESMO 2026 | CMV-associated adaptive NK cells influence response to IO in NMIBC
Bérengère Salomé, PharmD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the rationale behind focusing on CMV-associated adaptive NK cells and presents findings on their role in responding to immunotherapy (IO) in cancer, specifically in non-muscle invasive bladder cancer (NMIBC) treated with BCG. CMV-positive patients with adaptive NK cells have a survival advantage and higher chances of remaining tumor-free after treatment, and Dr Salomé highlights the development of strategies to induce these cells in patients who do not have them. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
